#United States #Heart Failure #Lasix ONYU #Burlington, MA #SUBCUT HF II

Trial Shows At-Home Diuretic Therapy's Viability

In an exciting advancement for heart failure management, SQ Innovation has announced the positive results of its SUBCUT HF II trial, demonstrating the effectiveness of at-home subcutaneous diuretic therapy. The findings were shared in the prestigious Journal of the American College of Cardiology, highlighting a promising shift towards enabling patients to self-administer their treatment with the innovative diuretic, Lasix® ONYU.

The trial presented a groundbreaking opportunity for patients suffering from heart failure, a condition affecting nearly one in four Americans throughout their lives. The study’s findings revealed that patients who received self-administered at-home treatment using Lasix® ONYU received comparable results to those who underwent traditional intravenous (IV) treatments in hospitals. Specifically, patients experienced a significant reduction in hospital stays, averaging around four fewer inpatient days per treatment episode.

Key Findings of the SUBCUT HF II Trial

Conducted across 20 NHS hospitals in the U.K., the SUBCUT HF II trial involved 172 patients aged between 34 to 92 years, all of whom were hospitalized for heart failure and required IV diuretic treatments. These patients were randomized into two groups; one group used the Lasix ONYU system for self-treatment at home via a wearable abdominal pump, while the other group continued with the standard inpatient IV treatment.

Pieter Muntendam, MD, the CEO of SQ Innovation, emphasized that the results underscore two essential pillars: the equivalent effectiveness of at-home diuretic treatment and the ability of patients to self-administer safely. The patients using the Lasix ONYU method administered approximately 900 mg of furosemide over their treatment period, which closely mirrors the hospital dosing, achieving similar treatment outcomes.

Dr. G. Michael Felker from Duke University elaborated on the real-world implications, accentuating the necessity to develop systems that empower patients to manage their conditions in the comfort of their homes. This trial not only promises to alleviate health system burdens but also opens avenues for future treatments across various medical conditions.

The Lasix ONYU Infusor

Lasix® ONYU, a novel drug-device combination, was previously approved by the FDA in October 2025, specifically for treating edema in adult patients with chronic heart failure. This system functions by administering 80 mg of furosemide consistently over five hours, ensuring effective diuresis similar to inpatient IV methods, but in a more controlled and home-accessible manner.

The trial's success demonstrates that patients no longer need to rely solely on nurse-administered IV medications, thus revolutionizing heart failure treatment protocols. The Lasix ONYU Infusor is designed to be easy to use, portable, and more convenient, allowing patients to maintain their independence while ensuring the necessary medical support is readily available.

Looking Ahead

Notably, this trial is part of a larger movement towards at-home therapies aimed at chronic conditions that typically require hospitalization. Ongoing efforts to refine home treatment protocols are aimed at minimizing hospital visits, improving patients' quality of life, and ultimately, enhancing healthcare systems.

With the SUBCUT HF II trial concluding with overwhelming success, the potential for the Lasix ONYU Infusor could pave the way for similar initiatives in other therapeutic areas, transforming patient care as we know it.